FLT3 and acute myeloid leukemia: It inhibits mutant and wild-type FLT3 in vivo at 0.1 and 0.5 μM, respectively, and has shown favorable activity and tolerability in phase I and II trials in acute myeloid leukemia, with QT prolongation as the dose-limiting toxicity.